LRM Therapeutics

LRM Therapeutics is a preclinical-stage biotechnology company focused on developing novel therapies that modulate the LRP1 (Low-density lipoprotein receptor-related protein 1) signaling pathway. Founded on research from UT Southwestern Medical Center, the company aims to address significant unmet needs in fibrotic diseases, such as chronic kidney disease and pulmonary fibrosis, as well as certain cancers. Their approach involves leveraging the multi-functional nature of LRP1 to regulate cellular processes including inflammation and tissue repair. The company is currently advancing its lead candidates through early-stage development to establish proof-of-concept.